Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis

Susu Han, Tao Huang, Wen Li, Xiyu Wang, Xing Wu, Shanshan Liu, Wei Yang, Qi Shi, Hongjia Li, Fenggang HouFrontiers in Oncology 2019 · DOI

TL;DR

This meta-analysis systematically reviewed existing studies to clarify the prognostic value of the CD44 protein and its variants (CD44v6, CD44v9) in advanced cancer patients. While CD44 showed a slight association with worse overall survival, CD44v9 emerged as a potential marker for poorer cancer-specific survival, particularly in patients receiving chemo/radiotherapy, though further validation is needed.

What Problem Does This Paper Address?

Cancer remains a significant global health challenge, and while treatments have advanced, outcomes for patients with advanced or metastatic disease are often disappointing due to resistance to therapies. Identifying reliable biomarkers that can predict prognosis and guide treatment is crucial. Cancer stem cells (CSCs) are implicated in tumor progression, metastasis, and treatment resistance, and CD44 is a well-known marker for these cells. However, the prognostic significance of CD44 and its various isoforms (different versions of the protein arising from alternative splicing) in advanced cancer patients has been inconsistent across studies, creating a need for a comprehensive evaluation.

Methods

The researchers conducted a systematic meta-analysis, adhering to the PRISMA guidelines, to pool data from existing studies. They searched multiple databases for relevant articles published up to April 2018. The core of their analysis involved calculating pooled Hazard Ratios (HRs) with 95% Confidence Intervals (CIs) from multivariable survival analyses reported in the selected studies. This approach allows for the assessment of the association between CD44/CD44v expression and various survival outcomes, including Overall Survival (OS), Disease-Free Survival (DFS), Progression-Free Survival (PFS), Cancer-Specific Survival (CSS), and Recurrence-Free Survival (RFS). To address potential random errors and assess the robustness of the findings, they also employed Trial Sequential Analysis (TSA). Subgroup analyses were performed to investigate specific scenarios, such as survival at ≥5 years and outcomes in patients receiving adjuvant therapy.

Datasets

This paper is a meta-analysis and does not introduce new datasets. Instead, it synthesizes data from 15 previously published studies that investigated CD44 and its isoforms in advanced cancer patients. These studies collectively included 1,201 patients. The data extracted from these studies included patient demographics, cancer type, treatment regimens, and survival outcomes.

Key Insights and Ideas

  • CD44's nuanced prognostic role: While often considered a general marker of poor prognosis, this analysis suggests CD44's association with overall survival is modest and requires further confirmation.
  • CD44v9 as a potential specific marker: The study highlights CD44v9 as a more promising indicator, particularly for cancer-specific survival in patients undergoing chemo/radiotherapy, suggesting it might be a more targeted prognostic factor.
  • The need for caution with current evidence: The Trial Sequential Analysis (TSA) is a critical component, indicating that despite some significant findings, the current body of evidence is not yet sufficient to draw definitive conclusions, underscoring the need for more robust studies.
  • Heterogeneity in findings: The paper implicitly points to the challenge of interpreting CD44's role due to variations in study designs, patient populations, and the specific CD44 isoforms investigated.

Key Results

  • CD44 and Overall Survival (OS): A slight association was found between CD44 expression and worse OS (HR = 2.03, P = 0.027). However, this association was not observed for OS at ≥5 years or in patients receiving adjuvant therapy.
  • CD44 and other survival outcomes: No correlation was found between CD44 expression and DFS, RFS, or PFS.
  • CD44v6 and Survival: CD44v6 expression was not associated with OS.
  • CD44v9 and Cancer-Specific Survival (CSS): CD44v9 expression was strongly associated with poorer 5-year CSS in patients treated with chemo/radiotherapy (HR = 3.62, P < 0.001).
  • Trial Sequential Analysis (TSA): TSA indicated that additional trials are needed to confirm the findings for both CD44 and OS, and CD44v9 and CSS, suggesting the current evidence is not yet conclusive.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small sample sizes and limited studies: The meta-analysis, while comprehensive, was based on a relatively small number of studies and patients for certain analyses, particularly for CD44v6 and CD44v9.
  • Geographical bias: Most included studies were conducted in Japan and the USA, limiting the generalizability of findings to other populations.
  • Study design: Only one study was a prospective trial; the rest were retrospective.
  • Lack of standardization: Cut-off values for CD44 expression varied across studies, making direct comparisons challenging.
  • Limited isoform analysis: While CD44v6 and CD44v9 were examined, the prognostic value of other CD44 variant isoforms (v1-v10) in advanced cancers requires further investigation.

Future work should focus on:

  • Prospective clinical trials: Conducting well-designed prospective trials is essential to validate the prognostic significance of CD44 and its isoforms.
  • Standardized reporting: Establishing standardized methods for defining CD44 expression (e.g., positive/negative based on a standard cut-off) is crucial.
  • Diverse cancer types: Investigating the role of CD44 and its isoforms across a wider range of advanced cancer types is needed.
  • Therapeutic targets: Further research into CD44 and CD44v9 as potential therapeutic targets for improving treatment outcomes in advanced cancer patients is warranted.

Summary updated

Abstract

<b>Objective:</b> Cancer stem cell marker CD44 and its variant isoforms (CD44v) may be correlated with tumor growth, metastasis, and chemo-radiotherapy resistance. However, the prognostic power of CD44 and CD44v in advanced cancer remains controversial. Therefore, the purpose of our study was to generalize the prognostic significance of these cancer stem cell markers in advanced cancer patients. <b>Methods:</b> Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from multivariable analysis to assess the associations among CD44, CD44v6, and CD44v9 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Trial sequential analysis (TSA) was also conducted. <b>Results:</b> We included 15 articles that reported on 1,201 patients with advanced cancer (CD44: nine studies with 796 cases, CD44v6: three studies with 143 cases, and CD44v9: three studies with 262 cases). CD44 expression was slightly linked to worse OS (HR = 2.03, <i>P</i> = 0.027), but there was no correlation between CD44 expression and DFS, RFS, or PFS. Stratified analysis showed that CD44 expression was not correlated with OS at ≥5 years or OS in patients receiving adjuvant therapy. CD44v6 expression was not associated with OS. CD44v9 expression was closely associated with poor 5-years CSS in patients treated with chemo/radiotherapy (HR = 3.62, <i>P</i> < 0.001). However, TSA suggested that additional trials were needed to confirm these conclusions. <b>Conclusions:</b> CD44 or CD44v9 might be novel therapeutic targets for improving the treatment of advanced cancer patients. Additional prospective clinical trials are strongly needed across different cancer types.
BibTeX
@inproceedings{han2019prognostic,
  author = {Susu Han and Tao Huang and Wen Li and Xiyu Wang and Xing Wu and Shanshan Liu and Wei Yang and Qi Shi and Hongjia Li and Fenggang Hou},
  title = {{Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis}},
  booktitle = {Frontiers in Oncology},
  year = {2019},
  doi = {10.3389/fonc.2019.00039},
}
Figure